RTX Secures $23B Navy Contract, Reinforcing Defense Backlog but Not Valuation Margin

What happened

RTX has reportedly won a $23 billion U.S. Navy contract, adding to its already record defense backlog of $119 billion as of June 30, 2026. The award aligns with the ongoing structural reset in global defense priorities, including replenishment of precision munitions and fleet modernization, which management has highlighted as a key demand driver. However, the market has already priced in strong defense demand, with RTX trading at 37.9x earnings and 21.7x EV/EBITDA, leaving no margin of safety. The company's ability to convert backlog into revenue and cash remains constrained by supply-chain disruptions and tariff pressures, with only about 25% of remaining performance obligations expected to be recognized within 12 months. Consequently, while the contract is a positive signal for demand, it does not change the fundamental valuation picture, and the stock remains a WAIT at current levels.

Implication

The $23B Navy contract reinforces the defense demand narrative and supports the long-term growth outlook for Raytheon, but it does not address the key risk of backlog conversion. Investors should monitor whether RTX can accelerate deliveries and improve free cash flow conversion, as backlog alone has not driven upside given current valuation. We maintain our attractive entry level near $195 and would consider upgrading if management demonstrates clear improvement in conversion metrics by Q1 2027. Conversely, if supply-chain or tariff issues worsen and free cash flow guidance is cut, the stock could face downside to the $190 bear case. Until then, the risk-reward remains unfavorable at current prices.

Thesis delta

The announcement of a $23B Navy contract strengthens the defense demand side of the story but does not alter the core investment thesis. The original thesis emphasized the need for backlog conversion into revenue and free cash flow, and this new award does not change the company's short-term conversion constraints. Therefore, we maintain our WAIT rating and view the stock as fully valued at current levels, with a preferable entry point near $195.